Relationship between symptoms and results on spirometry in adults seen in non-tertiary public health facilities presenting with preserved ratio impaired spirometry

Submitted: March 12, 2024
Accepted: August 2, 2024
Published: September 16, 2024
Abstract Views: 339
PDF_EARLY VIEW: 101
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Preserved ratio impaired spirometry (PRISm), defined by reduced forced expiratory volume in 1 second (FEV1) without meeting criteria for airway obstruction, is often encountered in clinical practice. The management of this heterogeneous condition in individuals with chronic respiratory symptoms is challenging, especially under limited diagnostic resources. Since 2020, all consecutive patients referred for spirometry at our institution have been invited to participate in our registry. Other than spirometry, no other physiological lung function testing is available in this public health service. Therefore, we reviewed our databank with the aim of assessing: i) the proportion of symptomatic patients aged 18 years or older referred for spirometry presenting with PRISm; ii) the rate of inhaled medication used in this group, suggesting a referral diagnosis of obstructive airway disease (OAD); and iii) the relationship between symptoms and results on spirometry in PRISM compared to a group with obstruction matched by FEV1. To this end, the COPD Assessment Test (CAT) and the Asthma Control Test (ACT) were conjointly responded to by 1032 participants, irrespective of the clinical suspicion. We found that 22% had PRISM, of whom 200 were paired with obstruction by FEV1 (68±10% of predicted). The CAT and ACT results were well-correlated in both groups (r=-0.727 and -0,698, respectively; p<0.001) and used to measure symptoms. Participants in the final sample (n=400) were aged 62±13 years; 70% were ever smokers; and 55% reported household exposure to biomass smoke (at least 5 years). The CAT responses were in the range of moderate symptoms (17±9) and ACT borderline for uncontrolled symptoms (19±5). The main differences were higher body mass index (33±7 versus 29±7 kg/m2; p<0.001) and proportion of females (72 versus 49%; p<0.001) in PRISm compared to obstruction. This group had lower exposure to tobacco (65 versus 76% of ever-smokers) but greater exposure to biomass smoke (61 versus 49%) (p<0.05 for all). The rate of inhaled medication use was as high in PRISm as in obstruction (80%). Notwithstanding matched FEV1, we found less prominent signs of airway disease in PRISM: marginally reduced FEV1/forced vital capacity (FVC) ratio (94±8% of predicted); higher expiratory flow between 25% and 75% of vital capacity, despite presumed lower lung volumes (lower FVC); and lower rate of bronchial hyperresponsiveness. In an identical multivariate model, FEV1 predicted symptoms of obstruction only. In conclusion, these data raise suspicion of a substantial rate of misclassification of individuals with PRISM as having OAD in healthcare facilities with constraints on diagnostic resources.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499. DOI: https://doi.org/10.1183/13993003.01499-2021
Miura S, Iwamoto H, Omori K, et al. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality. Sci Rep 2023;13:2988. DOI: https://doi.org/10.1038/s41598-023-29922-0
Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999;115:869-73. DOI: https://doi.org/10.1378/chest.115.3.869
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22. DOI: https://doi.org/10.1016/S0140-6736(20)30925-9
Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967;22:395-401. DOI: https://doi.org/10.1152/jappl.1967.22.3.395
Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018 Sep;12(9):755-767. doi: 10.1080/17476348.2018.1506331. Epub 2018 Aug 14. PMID: 30056777; PMCID: PMC6311385. DOI: https://doi.org/10.1080/17476348.2018.1506331
Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res 2014;15:89. DOI: https://doi.org/10.1186/s12931-014-0089-y
Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J 2020;55:1901217. DOI: https://doi.org/10.1183/13993003.01217-2019
Lu J, Ge H, Qi L, et al. Subtyping preserved ratio impaired spirometry (PRISm) by using quantitative HRCT imaging characteristics. Respir Res 2022;23:309. Erratum in: Respir Res 2023;24:31. DOI: https://doi.org/10.1186/s12931-022-02113-7
Wan ES, Balte P, Schwartz JE, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA 2021;326:2287-98. DOI: https://doi.org/10.1001/jama.2021.20939
Guerra S, Carsin AE, Keidel D, et al. Health-related quality of life and risk factors associated with spirometric restriction. Eur Respir J 2017;49:1602096. DOI: https://doi.org/10.1183/13993003.02096-2016
Wan ES. The clinical spectrum of PRISm. Am J Respir Crit Care Med 2022;206:524-5. DOI: https://doi.org/10.1164/rccm.202205-0965ED
Phillips DB, James MD, Vincent SG, et al. Physiological characterization of preserved ratio impaired spirometry in the CanCOLD study: implications for exertional dyspnea and exercise intolerance. Am J Respir Crit Care Med 2024;209:1314-27. DOI: https://doi.org/10.1164/rccm.202307-1184OC
Higbee DH, Granell R, Davey Smith G, Dodd JW. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med 2022;10:149-57. DOI: https://doi.org/10.1016/S2213-2600(21)00369-6
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70-88. DOI: https://doi.org/10.1164/rccm.201908-1590ST
Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54. DOI: https://doi.org/10.1183/09031936.00102509
Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65. DOI: https://doi.org/10.1016/j.jaci.2003.09.008
Pereira CAC, Barreto SP, Simões JG, et al. Valores de referência para espirometria em uma amostra da população brasileira adulta. J Pneumol 1992;18:10-22.
Schwartz A, Arnold N, Skinner B, et al. Preserved ratio impaired spirometry in a spirometry database. Respir Care 2021;66:58-65. DOI: https://doi.org/10.4187/respcare.07712
Han MK, Ye W, Wang D, et al. Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function. N Engl J Med 2022;387:1173-84. DOI: https://doi.org/10.1056/NEJMe2210347
Van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest 2010;138:393-406. DOI: https://doi.org/10.1378/chest.09-2622
Margretardottir OB, Thorleifsson SJ, Gudmundsson G, et al. Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study. COPD 2009;6:250-5. DOI: https://doi.org/10.1080/15412550903049157
Neder JA, Rocha A, Alencar MCN, et al. Current challenges in managing comorbid heart failure and COPD. Expert Rev Cardiovasc Ther 2018;16:653-73. DOI: https://doi.org/10.1080/14779072.2018.1510319
Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-76. DOI: https://doi.org/10.1183/09031936.04.00012704
Lamprecht B, Vanfleteren LE, Studnicka M, et al. Sex-related differences in respiratory symptoms: results from the BOLD Study. Eur Respir J 2013;42:858-60. DOI: https://doi.org/10.1183/09031936.00047613

Ethics Approval

The study protocol was approved by the Ethical Review Committee of the Jundiai Medical School (number 2.198.023).

How to Cite

Martinelli, Marcos, Eduardo V. Ponte, Daniel Antunes S. Pereira, Giulio Checchinato, Bruna Eduarda Gandra, Bruno Maciel, and Alcides Rocha. 2024. “Relationship Between Symptoms and Results on Spirometry in Adults Seen in Non-Tertiary Public Health Facilities Presenting With Preserved Ratio Impaired Spirometry”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2024.2990.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.